

ASX ANNOUNCEMENT

BENITEC BIOPHARMA LIMITED (ASX: BLT, OTC: BTEBY)

11 March 2015

FOURTH PATIENT DOSED IN BENITEC'S TT-034 TRIAL FOR HEPATITIS C

- **Second patient in the second cohort dosed at Duke**
- **Next patient (the third in the second cohort) being prepared for dosing**

Sydney, Australia: Benitec Biopharma is pleased to advise that the fourth patient in the company's 'first in man', Phase I/IIa clinical trial of TT-034 for hepatitis C, has today, been dosed at the Duke Clinical Research Unit. The fifth patient is well advanced in their preparation for dosing.

As previously announced, the dosing follows the DSMB's review of the safety data from the first patient in this cohort.

All three of the patients in the second cohort receive a dose of TT-034 of 1.25×10^{11} vg/kg, a concentration that is a half log higher than the doses administered in the first cohort. This dose level is still below the concentration expected to inhibit hepatitis C viral replication and data from the second dosing cohort is therefore expected to serve primarily as a further safety assessment.

More detail on the TT-034 trial

TT-034 is a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single administration. TT-034 targets the hepatitis C viral RNA at three separate, highly conserved sites. As such it acts as a "triple therapy" even though it is a monotherapy, and minimises the ability of the virus to mutate and escape the therapy. Once it reaches the liver cells it enters the nucleus and produces three separate short hairpin RNAs continuously for the life time of the cell. Thus it has the potential to not only treat the existing HCV infection but to guard against reinfection for months to years without the need to re-treat. It has been extensively tested in pre-clinical in vivo studies and no adverse effects were seen at any therapeutic dose. However, as it is regulated as a gene therapy, the trial design is to primarily ensure that treatment with TT-034 is safe, hence the gradual dose escalation.



For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

<i>Company</i>	<i>Investor relations</i>
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Kyahn Williamson Buchan Consulting Tel: 61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX:BLT; OTC:BTEBY) which has developed a patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Hepatitis C and B, drug resistant lung cancer and wet Age-related Macular Degeneration. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa. For more information visit www.benitec.com.